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1. Introduction 
The origin of neuroblastoma was first described in Berlin, by Virchow in 1864, when he gave it 
the name “Glioma”. In 1891, Marchand observed similarities between this tumor and the 
ganglia of the Sympathetic Nervous System in its developmental phase, and Wright 
demonstrated that the cellular type of this tumor was similar to the one observed in the 
embryonic stage of the medulla of the adrenal glands. The name Neuroblastoma was 
proposed by James Homer Wright in 1910, while Morgan observed microscopically an adrenal 
tumor with fibrillar characteristics. In 1914, Herxheimer, using Bielschowsky’s method of 
silver staining, showed that the fibrillar structures were nerves fibers originating in the nerve 
cell proper, and not in the cells of the sheaths nerve as it has been noted in the case of a benign 
ganglioneuroma. Robertson indicated that any important series of these tumors of the neural 
crest were characterized by a variety of histological grades ranging from benign, with well 
differentiated cellular elements, to highly anaplastic forms. Rinscheid observed little fibrillar 
elements inside the tumor cells that were similar to those observed in normal neuroblasts. 
These findings were later confirmed by Murray and Stout in investigations done in vitro 
cultures of Neuroblastoma cells. Pepper described a supposed propensity for hepatic 
metastases (Pepper Metastases) in young children with Neuroblastoma, and Hutchison 
described a predilection for skeletal metastases(especially in the skull)  from a primary 
Adrenal lesion in older children (Hutchinson metastases) In 1916, William Barlett, in Missouri, 
achieved the first successful tumor resection in a boy that survived for more than 15 years. 
Cushing and Worbach reported in 1922, in a 10 review, the progression of neuroblastoma to 
ganglioneuroblastoma. In 1928, Fill and Dresser used radiotherapy as treatment for 
neuroblastoma without success. Cytotoxic agents were introduced in 1940 without therapeutic 
results. In 1957, Mason published a report of a boy with neuroblastoma whose urine contained 
amine vasoconstrictors. This discovery contributed to the best understanding of 
neuroblastoma and its possible origin in the sympathetic nervous system [1].  
He noted that it was common to have spontaneous regression of microscopic group of cells 
within the Neuroblastoma, called Neuroblastoma in Situ. According to Beckwith and Perrin, 
in 1963, this spontaneous regression occurred almost 40 times more frequently than the 
number of well defined true clinical cases. 
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In 1965, James and colleagues (St Jude’s Children Hospital), using combination 
chemotherapy appeared to have a small effect on the survival of these patients. 
2. Epidemiology 
The incidence of cancer children is analyzed according to the International Classification of 
Cancer in Childhood [2], which since its first edition has taken into account the classification 
of Birch and Marsden [3] which divides all the morphologies in twelve groups and forty 
seven diagnostic subgroups. The third edition of the International Classification of Cancer of 
Childhood is based on the third edition of the International Classification for Oncology 
(CIE-OR 3) [4], where all the morphological changes published in this classification have 
been upgraded. Neuroblastoma and Ganglioneuroblastoma are within group IVa of this 
classification. 
Neuroblastoma (NB) is the most common neural crest derived extra cranial solid tumour of 
childhood and arises from sympathetic nervous tissue origins. It’s the most common solid 
tumour in children younger than 5 years of age. It is the fourth most common paediatric 
malignancy, accounting for 7-10% of all childhood cancers and the most common cancer 
diagnosed during infancy with a median age at diagnosis of 18 months. Neuroblastoma is 
the fourth pediatric most frequent tumor and it burdens 6-10% of all cancers of the 
childhood. The highest incidence is during the first year of life, when about 1-2% of the cases 
are congenital tumors. It is often described as enigmatic and unpredictable disease and the 
incidence of spontaneous regressions is much greater than in any other human cancer [5, 6]. 
The age range is wide, including children older than 5 years of age, in which only 10% of the 
cases are reported [5]. 
There are geographical differences in the incidence of Neuroblastoma. In the United States  
the frequency is reported to be 8-9: 1000000 children, while  a screening of the population in 
Japan in the years 1984-2002 estimated the incidence to be  approximately 180:1 000 0000 [6]. 
In the United Kingdom  only around 75 new cases have been diagnosed  every year, in 
general,  about  6 of each 100 cases of cancer in children  younger than 15 years in that 
country [5,6,7]. In Germany, one of each 5000 children is affected, that is to say that in that 
country, every year, about 150 children are diagnosed with this disease. In Cuba,  between 
the years 2000-2003, it represented 3,3% of tumors in infants [8]. 
Neuroblastoma is more common in Caucasian children with a slight prevalence in boys. The 
ratio of male to female is 1.3: 1 [12]. 
It is difficult to find population data about the mortality for this tumor because the data on 
mortality, published by the statistical registrations at world level, are based on the anatomical 
localization of the tumor and not related to its morphology, This makes it difficult to obtain 
accurate data to evaluate the mortality rate of Neuroblastoma, due to its propensity to present 
itself in multiple anatomical locations. Therefore we suggest that the information about infant 
mortality be reported by diagnostic groups as well as the incidence.  
3. Cytogenetic and molecular characteristics 
According to Knudson and Strong (1972), 20% of All neuroblastomas are inherited through 
an autosomal dominant pattern, whether solitary, bilateral or multifocal tumors. It can have 
www.intechopen.com
 
Neuroblastoma – Molecular Basis for Diagnosis and Staging System 
 
317 
several abnormalities in the karyotype, but the deletion of the short arm of chromosome 
number 1 is found in 70-80% of all patients with neuroblastoma14. The malignant 
transformation and persistence of the state of differentiated cells of the neural crest can be the 
result of the failure of these cells to respond to the normal signals that are responsible for the 
normal morphological differentiation. The factors involved in the cascade of events are not 
well known, but probably involve one or more lines of the binding receptor. One of the more 
popular and well studied lines is the Nerve Growth Factor (NGF) and its receptor (NGFR).  
Tumours with N-myc amplification or loss of heterozygosis for chromosome 1p generally 
have a poor prognosis. NB cells vary in relation to their differentiation stage, with 
aggressive NB tumors deriving from more immature NB cells. These NB tumors may be 
present as phenotypically distinct groups of NB cell types (i.e.neuroblastic, neuroendocrine) 
organized in lobular structures with a central necrotic/hypoxic zone. Recent evidence has 
demonstrated that NB cells growing in these necrotic/hypoxic zones undergo a gene 
expression switch involving decreased expression of neuronal/neuroendocrine marker 
genes, but induced gene expression of neural crest sympathetic progenitor markers. These 
data, indicating that hypoxia causes dedifferentiation of NB cells to proliferative immature 
neuroblast-like cells, suggest potential activation of epithelial mesenchyme transition 
mechanisms (EMT). Although EMTs occur during critical phases of embryonic development 
in many animal species, it is now well recognized that EMT is a potential mechanism for 
cancer progression. However, the activation of these events in hypoxic NB cells remains 
largely undetermined [16]. 
Recently, continuous lines of human NB cells in culture have established that enzyme activities 
associated with neurotransmitter biosynthesis have been detected in approximately 10 
independently derived cell lines [10]. The unresolved questions are whether and to what 
extent an individual tumour consists of a mixture of functionally differing neuronal 
phenotypes and whether and to what extent a single NB cell may have the potential for 
synthesis of more than one transmitter. Results of several combined clinical and biochemical 
studies suggest that the cells established in culture reflect the characteristics of the tumour 
from which they were derived. Although karyotype analysis of the human cell lines has 
revealed the presence of consistent marker chromosomes suggestive of clonal origin of 
individual neuroblastomas, the possibility of functional diversity and multipotentiality of the 
tumor cells in vivo cannot be explored by studying the tumour cell population as a whole. To 
obtain evidence regarding functional properties as well as phenotypic stability of human NB 
cells, it was isolated clones from the NB lines SK-N-SH and SK-N-MC and began their 
characterization. These 2 parental lines were compared to a hitherto uncharacterized set of NB 
lines, SK-N-BE(1) and SK-N-BE(2), isolated at different times from the same patient and 
possessing several biological and biochemical features in common [17]. 
Genetic studies have an important role in formulating the prognosis in children with 
neuroblastoma, because certain acquired genetic abnormalities in the tumour cells correlate 
closely with the clinical outcome. Established indicators of the aggressiveness of the tumour 
and poor outcome include the deletion of the short arm of chromosome 1 (1p), the 
amplification of the N –myc gene, and near diploidy or near tetraploidy. Conversely, the 
presence of 1p, single copies of N -myc, near triploidy, and expression of the TRK gene are 
significantly associated with a favorable prognosis. Recent methods revealed that the gain of 
material from chromosome 17 is the most frequent genetic abnormality of NB cells, with an 
incidence ranging from 63 to 83 percent. This gain may consist of an entire chromosome 17 
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(e.g., tetrasomy17 in a triploid tumour) or of only the distal segment of the long arm, 17q21–
qter. Such a partial gain is strongly associated with risk factors: age of more than one year, 
presence of advanced disease, deletion of 1p, amplification of the N –myc gene, and 
unfavourable ploidy. The principal mechanism underlying partial gain of 17q is an 
unbalanced translocation, with a variety of partner chromosomes. The segment on the partner 
chromosome distal to the breakpoint is lost, and a segment of 17q translocates to that site [18].  
It is also found on virtually all unipotent and multipotent colony-forming cells, on blast 
colony-forming cells, and on precursors of colony-forming cells detectable in long-term 
marrow culture. This antigen has been identified by antibodies MY-10, BI-3C5, ICH3, and 
12-8. Previous work has demonstrated that isolated autologous CD34+ marrow cells can 
engraft lethally irradiated baboon, It has been observed that the CD34 antigen is not 
detected on tumour cells from patients with most solid tumors including breast cancer and 
neuroblastoma. In viitro studies have demonstrated that immunoadsorption with antibody 
12-8 can be used to separate normal marrow progenitors from tumor cells. There is 
considerable evidence suggesting that ATP functions as an extracellular signaling molecule 
in neural and nonneural mammalian tissues. In central and peripheral synapses, ATP 
mediates fast excitatory neurotransmission. In the autonomic nervous system, ATP is a 
major purinergic cotransmitter that is often colocalized in secretory vesicles with 
norepinephrine or acetylcholine. In the vascular system, aggregating platelets secrete ATP 
and ADP, which stimulate the release of nitric oxide and other vasodilators from the 
endothelium. In the immune system, ATP modulates macrophage phagocytosis and mast 
cell degranulation. In the human airway epithelium, ATP stimulates trans-epithelial ion 
transport, an effect that may underlie the therapeutic effect of ATP and UTP in the treatment 
of cystic fibrosis-related lung disease. It has been postulated that these responses to 
extracellular ATP are mediated by specific plasma membrane receptors, called P2 purinergic 
receptors. Based on agonist selectivity and signalling properties, five subclasses of P2 
receptor have been tentatively defined: three subclasses of receptors (P2T, P2U, and P2y) 
that are believed to signal through G proteins, one subclass (P2X) that is believed to be a 
ligand-gated cation channel, and one subclass (P2z) that is present on mast cells, 
macrophages, and fibroblasts, but whose signalling mechanism is less well understood. G 
protein-coupled P2 receptors are found in numerous cultured cell lines, where they have 
been shown to activate signal transduction systems that involve the breakdown of 
membrane phospholipids and the elevation of cytoplasmic free Ca2+. Ionotropic P2X 
receptors carry Na+, K+, and Ca2+ currents and appear to be predominantly expressed in 
neural and neuromuscular tissues. A more complete characterization of this putative family 
of P2 purinergic receptors has been hampered by the complete lack of specific P2 receptor 
antagonists, radioligands, and cloned receptor cDNAs. To circumvent this difficulty, we 
have used a Xenopus laevis oocyte expression cloning strategy to isolate a cDNA encoding a 
functional P2U receptor from NG108-15 neuroblastoma x glioma hybrid cells [19]. 
Of considerable interest in connection of herpes simplex virus 1 (HSV-1) with this disease 
are the genes that confer the capacity to replicate in the central nervous system (CNS) 
tissues. The y134.5 gene is located in the inverted repeats flanking the long component of 
viral DNA and therefore the gene is present in two copies per genome Its location is 
consistent with previous reports showing that a locus that affected the capacity of the virus 
to multiply in the CNS tissues mapped at the right end of the long component of HSV DNA 
in the prototype arrangement [20]. 
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4. Forms of clinical presentation 
Neuroblastoma has been called the great imitator due to its varied clinical presentations, 
related to the anatomical distribution of the Sympathetic Nervous System, location of the 
primary tumor, metastasis and metabolic byproduct of the tumor.  
 
From: Bowman LC et to 1994 J. Clin Oncol 9: 1599 - 1608 
Fig. 1. Anatomical distribution of the sympathetic nervous system and frequency of 
localization of Neuroblastoma according to regions. 
Seventy five percent of primary Neuroblastoma  occur in the abdomen, and most of these  
happen in the Adrenal (50%) Glands. As a result, most of the children affected complain of 
abdominal discomfort, such as fullness and, or abdominal distension. The most common 
symptoms are related to pain in the abdominal mass and the bones, secondary to metastatic 
neuroblastoma. The complaints of fatigue, pain in bones, and changes in intestinal habits 
can contribute to the exact diagnosis. The physical findings could include hepatomegaly, 
hypopigmented subcutaneous nodules, big, firm irregular abdominal mass.  
Typically children with localized disease are asymptomatic, while {the} children with 
disseminated neuroblastoma are generally sick and they can have systemic manifestations, 
including fever of unknown origin, marked weight loss, anorexia, diarrhea, growth 
problems, general malaise, irritability and bone pain, difficulty walking, subcutaneous 
nodules, hepatomegaly, adenopathy, asthenia, paleness, proptosis, periorbital hematoma, 
hypertension, paraparesis, paraplegia, cerebellar ataxia [9,10]. 
www.intechopen.com
 
Contemporary Pediatrics 
 
320 
At the time of diagnosis, the site of the neuroblastoma is predictable depending on the 
patient’s age. Infants often present with compression of the Sympathetic Ganglia in the 
thoracic region which could manifest, for example, as a Horner’s Syndrome (myosis, 
anhydrosis, and palpebral ptosis palpebral) or as a Superior Vena Cava Syndrome. Older 
children typically present with abdominal pain because as it was mentioned previously, 
more than {of} 40% of neuroblastomas originate in the adrenals. More than 50% of the 
patients who present with neuroblastomas have metastatic disease. The most frequent sites 
of involvement are, the bone marrow, bones, liver, lymph nodes and skin [10]. 
The appearance of other syndromes also related to neuroblastoma is not surprising; 
Pepper’s Syndrome, for example, occurs in infants with liver metastasis which causes 
respiratory insufficiency. Described by William Pepper in 1901, it was identified as a 
primary localized tumor with metastatic disease limited to the skin, liver, and bone marrow; 
in children it has been associated with neuroblastoma stage IVs. This syndrome is the only 
entity that only occurs in children younger than 1 year of age. It generally confers a better 
prognosis when spontaneous regression is associated with this entity; however some 
children with stage IVs can die from massive hepatomegaly, respiratoty failure, and 
generalized sepsis. Hepatoblastoma should be considered in the differential diagnosis [9,10]. 
Babies called "Blueberry muffin" are infants whose neuroblastoma has randomly 
metastasized to subcutaneous areas. These nodules become intensely red when first touched 
followed by blanching, lasting several minutes. This response is probably secondary to the 
discharge of vasoconstrictors derived from metabolic byproduct of the tumor. These 
nodules can be the diagnosis of neuroblastoma [11]. 
Extensive metastases of neuroblastoma to bone can produce bone pain and as consequence, 
limping and pathological fractures. Neuroblastoma involving the paravertebral ganglia can 
extend through nerve foramina, and cause spinal cord compression with subsequent 
paralysis. Infrequently, neuroblastoma can metastasize to the retrobulbar region, 
progressing quickly to a unilateral proptosis without pain, to periorbital edema, and to 
ecchymosis of the superior part of the eye, characterized as the syndrome of Hutchinson. 
Those signs can be mistaken for trauma in a child [23]. This syndrome can also be 
characterized by preauricular, ipsilateral  sub maxillary and upper cervical adenopathy, as 
well as metastasis to lymph nodes of the retroperitoneum, mediastinum and supraclavicular 
region. 
Most neuroblastomas produce catecholamine like substances as metabolic byproducts that 
are responsible for some of the most interesting manifestations observed in children with 
this disease. For example, Kerner-Morrison's syndrome causes secretory refractory diarrhea, 
producing hypovolemia, hypokalemia, and prostration. This is secondary to the vasoactive 
intestinal peptide (VIP) secreted by the tumor. This syndrome is usually associated with 
ganglioneuroblastoma or ganglioneuroma [11].  
The diagnosis of neuroblastoma requires the participation of pathologists who are well 
familiarized with children’s tumors. Some of the cells cannot be differentiated from small, 
round, blue cells found in other childhood tumors (such as lymphomas, primitive 
neuroectodermal tumors and rhabdomyosarcoma) by simple light microscopy. The 
evidence necessary to make the differentiation of neurosympathetic origin should be 
demonstrated by immunohistochemistry, electron microscopy, elevated levels of serum 
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catecholamines (dopamine, noradrenaline) or catecholamine metabolites in the urine, 
vanillylmandelic acid (VMA) or homovanillyc acid (HVA) [10]. 
The minimum criteria required to determine a diagnosis definition of Neuroblastoma has 
been recently established by an international group of experts and the corresponding 
participants. These are unequivocal pathological diagnosis or the unequivocal presence of 
scyncytium cells in the bone marrow, as mentioned before [10, 32].  
The staging and monitoring of disease in patients with NB are major areas of application for 
diagnostic imaging methods. Thus, diagnostic studies that enable accurate tumour staging 
should help in treatment planning and reduce unnecessary surgery. The current staging 
evaluation of patients with NB consists of computed tomography (CT) or magnetic 
resonance (MR) imaging of the primary tumour, a skeletal survey and either bone 
scintigraphy or metaiodobenzylguanidine scintigraphy for skeletal metastases, and bone 
marrow aspiration and biopsy for marrow disease. CT has a reported accuracy of about 80% 
in tumor staging; when CT is complemented with scintigraphy or bone marrow aspiration, 
the accuracy has been reported to increase to 97% (15). MR imaging has also yielded high 
sensitivities (85%–100%) in the detection of abdominal disease and distant metastases [33]. 
There are organized systems to classify Neuroblastomas. Historically, each organized 
system has represented a temporary improvement in the understanding of this tumor. 
However, the existence of so many systems has not only confused the literature, but it has  
also complicated the comparison of studies among the different institutions27. A standard 
of clinical criteria exists for  diagnosis, staging and response to therapy known as The 
International Neuroblastoma Staging System (INSS), determining the necessity to obtain 
biological (histopathological and genetic) data to create therapeutic new groups 
internationally. In 1984, Shimada classified the neuroblastomas correlating their 
histopathological features with their clinical behavior. With this purpose, Shimada divided 
neuroblastomas into favorable and unfavorable categories, depending on the grade of 
differentiation of the neuroblasts, quantity of Schwannian spindle cell stroma, the index of 
mitosis- karyorrhexis, and the age  at diagnosis [12]. 
It has been observed that there are two types of Neuroblastoma with very different 
prognosis, which do not  differ either biochemically or  histologically, but from the genetic 
molecular aspect which  allows the  determination of unfavorable risk factors Amplified N-
myc, deletion of 1p, DNA euploidy, CD44 and N-level. These risk factors are rarely found in 
children younger than 1 year of age, but they are present in one third of Stages III and IV 
Neuroblastoma in children older than 1 year of age [13]. 
At this moment N-myc is considered to be the best genetic molecular parameter to define 
risk groups. For many years the patient's age and the stage of the disease at  the moment of 
diagnosis were the two variables most  significant in predicting prognosis in neuroblastoma. 
Evans found that the nursing infants younger than 1 year old with stages I, II and IV-s had 
significantly better prognosis. Patients older than 1 year of age and those with more 
advanced stages, that is to say, III and IV, had worse prognosis. The worst survival 
prognosis is observed in children older than 1 year of age, in stage IV and with cortical bone 
metastasis. The site of the primary tumor was also considered a predictor of survival 
according to some investigators. The patients with tumors in neck, pelvis and mediastinum 
have better prognosis when compared with those that present with tumors in the 
retroperitoneal space (paraspinal or Adrenal Glands) [9,13]. 
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CCG or Evans System POG* System INNS** System 
Stage I 
Tumor confined to the 
organ or structure of origin
Stage A 
Complete microscopic 
resection of primary tumor 
with or without residual 
microscopy. Intracavitary 
lymph nodes not adhered to 
the primary tumor and 
histologically free of tumor. 
Positive lymph nodes 
adhered to the surface or 
inside the tumor. 
Stage 1 
 Localized tumor, microscopic 
complete resection, with or without 
microscopic residual disease. 
Ipsilateral lymph nodes negatives for 
microscopic tumor. Positive lymph 
nodes adhered to the resected  tumor 
Stage II 
Tumor that extends {for} by 
continuity beyond the 
original organ, but it 
doesn't cross the midline. 
Positive regional ipsilateral 
lymph nodes. 
Stage B 
Microscopic incomplete 
resection of the primary 
tumor. Lymph nodes and 
liver similar to  stage A. 
Stage 2 A 
Localized tumor, with microscopic 
incomplete resection. Representative 
ipsilateral lymph nodes not adhered, 
negatives for microscopic tumor. 
Stage 2B 
Localized tumor, microscopic complete 
or incomplete resection, ipsilateral 
lymph nodes or adhered positive 
nodes  Contralateral lymph nodes 
negative for microscopic tumor.  
Stage III 
Tumor that extends {for} by 
continuity beyond the 
midline, positive bilateral 
lymph nodes. 
Stage C 
Complete or incomplete 
resection of the primary 
tumor. Lymph nodes not 
adhered to the primary 
tumor, histologically positive 
for tumor, liver similar to the 
stage A 
Stage 3 
Unilateral unresectable tumor that 
crosses the midline, with or without 
positive regional lymph nodes; or 
unilateral tumor that is localized, with 
positive regional contralateral  lymph 
nodes; or tumor in the midline that has 
extended bilaterally by continuity or  
by involving lymph nodes. 
Stage IV 
Metastasis to Bone, bone 
marrow, soft tissue  and 
distant lymph nodes. 
Stage D  
Disease spreading beyond 
Intracavitary lymph nodes 
Stage 4 
Any primary tumor with distant 
metastasis to lymph nodes, bone, liver, 
skin, bone marrow or other organ 
(except the defined by Stage IVs). 
Stage IV-S 
Defined as Stages I or II, 
except for the presence of 
distant disease confined to 
skin, liver or bone marrow 
(without bone metastases) 
or both.  
Stage D-S 
Nursing children  younger 
than 1 year-old, with Stage 
IVs disease (CCG  Staging  
Stage 4 S 
Localized primary tumor (as define in 
the Stage 2A or 2B, with limited 
spread to liver, skin, bone marrow). 
Nursing infants younger than one 
year old. 
Classification by Shimada and Jhosi (1992 and 1999) establishes a prognostic classification based on 
histological features, the patient's age, presence or absence of stroma, the grade of differentiation and 
the index of Mitosis-Karyorrhesis (MKI). 
Table 1. Neuroblastoma Staging System. Comparison of the three systems 
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Poor stroma Favourable histology 
Well differentiated  
Intermediate 
Unfavourable histology 
Nodular 
Poor stroma MKI < 200/5000 MKI <100/5000 
Age <  18m MKI >100/5000 MKI < 100/5000 
Age 18- 60m Differentiated Undifferentiated 
Age <5 years old None All 
FROM: Grosfeld JL et to 2002 Cir. Pediatr 12: 1345-46 
Table 2. 
5. Diagnosis 
To carry out the diagnosis of this disease, it is necessary to keep it in mind,  to take into 
account the epidemiological aspects described before,  the signs and symptoms described in 
the forms of clinical presentation, added together to the study of the catecholamines,  the 
blood chemistry result: complete hemogram with differential, glycaemia, urea, creatinine, 
study of {the} hepatic (TGP, TGO, alkaline phosphatase) function, radiological study of the 
thorax including CAT Scan and MRI. If needed, abdominal ultrasound, bone scan included 
the bone gammagraphy, bone marrow examination, histological study (included 
immunohistochemistry) of a biopsy of the lesion. 
 
Tyrosine 
 
DOPA            AHV 
 
Dopamine 
 
Norepinephrine  AVM 
 
Epinephrine 
 
The following studies are being referred to due to their significant importance. [10]: 
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 The examination of the bone marrow aspirate is characterized by the presence of 
malignant cells, that can present a diffuse pattern or, in its characteristic way of rosettes 
(Homer-Wright rossetes). They appear in nests or islands of atypical cells separated by 
septa , disseminated among the normal cells of the bone marrow. 
 Study of levels of Catecholamines in blood and in urine. With sensitive technique, in 
more than 95% of these tumors elevated urinary metabolites can be detected: 
homovanilic acid (AHV) and {the} vanillylmandelic acid (AVM). 
Catecholamine is  the generic name of the amines derived from catechol or 1,2-bencenodiol; 
being the most important epinephrine, norepinephrine and their precursor, DOPA 
(dihydrophenylalanine), of sympaticomimetic action. In the following figure it is show in a 
simplified manner [10]: 
 By means of a biopsy it  is possible  to obtain the two histological varieties of this tumor: 
Ganglioneuroblastoma (morphological code 9490/3) and Neuroblastoma 
(morphological code 9500/3) 
In half of the cases, metastasis is already present at the time of diagnosis, especially in 
regional organs and distant lymph nodes, in the bone marrow, bone, liver, skin, and rarely 
in the Central Nervous System. 
6. Differential diagnosis 
Fundamentally with: non Hodgkin lymphomas, Ewing sarcoma and rhabdomyosarcoma 
[10, 14]. 
  
Fig. 2. Cells of a nerve ganglion with neuroblastoma. 
7. Prognostic factors  
Certain biological variables have been identified that affect the prognosis of children with 
neuroblastoma. The specific examples include the aneuploidia of the DNA in the tumor and 
the amplification of the oncogene N-myc. The amplification of N-myc happens in 20% of the 
primary neuroblastoma and it is associated with a neuroblastoma subset that has a high 
metastatic potential and a POOR prognosis. It is thought that N-myc contributes to the 
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aggressive behavior of neuroblastoma. However, the precise  role of non-amplified N-myc  
in tumors is unknown [9,15,16]. 
The hyperdiploidity of the DNA in tumors is associated with a favorable prognosis. The 
amplification of N-myc is associated with a POOR prognosis in children older than 1 year of 
age, but not in children younger  than 1 year of age. The amplification of N-myc is 
associated with the deletion of the short arm of chromosome 1p and a gain  on the long arm 
of the chromosome 1755. In neuroblastoma, areas consistently showing heterogenecity of 
the chromosome (LOH) include bands of the chromosomes 1p36, 11q23, and 14Q23qter. In 
2000, Maris et al. informed the Children’s Cancer Group (CCG) that the deletion  of the 1p 
predicted a lower survival independently, but not the overall survival. The clinical relevance 
of 14q LOH is uncertain at this time. There are other prognostic variables such as the level of 
ferritin in serum, of neuron-specific enolase (NSE), and the nutritional status of the patient 
[17, 18]. 
Different prognostic factors have been described in Neuroblastoma, but most of the 
reviewed authors classify them as favorable factors and unfavorable factors [10, 19, 20]. 
Favorable factors: 
 Early clinical stages (I, II, IVS) 
 Location: thorax, pelvis, and neck 
 Age: younger than one year of age 
 Favorable histological pattern of Shimada:  
 STROMA rich in cells of Schwann, diffuse 
 Neuroblasts with nuclear and cytoplasmic differentiation toward node cells. 
 MKI Index (mitosis / karioresis) related  to age: younger than 18 months: MKI <       
200/5000; from 18 to 24 months < 100/50.000 and from 2 to 5 years not 
 Normal homovanillic acid (HVA) in urine.  
 Normal serum levels of ferritin and neuron-specific enolase.  
 Negative intestinal vasoactive peptide. 
 Good Nutritional State 
 DNA aneuploidy. 
 Oncogene N-myc < 10 amplifications 
 Absence of metastasis.  
Other factors associated separately, to a favorable evolution and inversely related to  the 
amplification of the gene N-myc they are: 
 The expression of the gene that codes the receptor of the factor of High Neural 
Affinity named proto oncogene TRK-TO 
 The expression of the receptor Low Neural Affinity (LNGFR) 
 .H-ras p21 oncogene expression 
Unfavorable factors: 
 Stage: III and IV 
 Location: retroperitoneum 
 Age: older than 1 year old 
 Histologic pattern: undifferentiated neuroblastoma 
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 Increase in the index homovanillic acid/ vanillylmandelic acid. 
 Increase in serum level of ferritin, neuron-specific enolase and LDH. 
 Increase of intestinal vasoactive peptide. 
 Malnutrition. 
 DNA diploidy 
 Oncogene N-myc with> 10 amplifications 
 The loss of expression of the glycoprotein CD44 on the surface of the tumor. 
 Metastasis to regional lymph nodes. 
 Increased levels of p-glycoprotein after chemotherapy 
 The activation of gelatinase A is related with high expression of MT-MMP-1 
(membrane-type matrix metalloproteinase-1) in neuroblastoma cells, and in turn it is 
related with advanced stages and with worse outcome. 
NOTE: p-glycoprotein is the protein produced by the gene that code for drug multiresistance. 
Contrary to what has happened {to} with other embryonic tumors in children, in which the 
combined treatment of the different therapeutic modalities of the cancer has achieved a 
considerable increase in survival, the prognosis of neuroblastoma continues to be  uncertain. 
8. Treatment 
The treatment of NB is determined by the stage of the tumor at time of diagnosis. Disease 
that is regionally limited is potentially resectable, while disease that is locally extensive or 
disseminated is usually not resectable.  
In 1988, the Pediatric Oncology Group (POG) carried out a study that revealed that 89% of 
patient with localized neuroblastoma that were treated by surgical resection had a survival 
of only 2 years. Additionally, chemotherapy seemed to have offered no advantage residual 
disease was present in these patients 34. Therefore, for patients with favorable stage, surgery 
is the main form of therapy. The most important goals of surgery are: to determine an exact 
diagnosis, to excise completely the entire primary tumor, to provide the exact surgical 
findings, the adjuvant therapy in delayed primary  surgery, and to remove  residual disease 
in second look surgery[21]. 
Since surgery is only done in early stages of neuroblastoma (stages I and II)  multi agent 
chemotherapy is the conventional therapy for patients in the most advanced stages of 
neuroblastoma. In children younger than one year of age with disseminated neuroblastoma, 
favorable results have been obtained with the combination of chemotherapy and surgery. In 
contrast, children older  than 1 year of age with neuroblastoma in advanced stage have a 
very low survival rate, despite intensive multimodality therapy [36]. Due to these 
observations, in Japan, during the 1980’s it was proclaimed that an aggressive exploration in 
children younger than 6 months with  catecholamines in the urine could uncover  earlier 
neuroblastoma which could result in better outcome. In Europe and North Americ 
controlled clinical tests were carried out in the affected population and when comparing 
results with those of the Japanese study , no benefits were found with this investigation [22]. 
In spite of these confusing studies, symptomatic treatments are available for  patients with 
neuroblastoma. The Adrenocortical Hormone (ACTH) is thought to be quite effective, 
although some patients are resistant. Plasmapheresis and gamma globulin have been used 
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in the treatment of selected patients with neuroblastoma; however, it is thought that 
treatment with chemotherapeutic agents produce better neurological results [23]. 
The common chemotherapeutic agents used to treat Neuroblastoma include cisplatin, 
doxorubicin, cyclophosphamide, and the epipodophyllotoxins (teniposide and etoposide). 
The protocols with combination of narcotics have used strategies that take advantage of 
drug synergism, mechanism of toxicity, and variety of adverse effects. Despite the different 
drug combinations, the rate of cure has not been significantly affected. The long term 
survival of patient with metastatic neuroblastoma is low. It is believed that this is due to the 
presence of a large number of non-proliferating cells in the tumor. However, in 
neuroblastoma treated with chemotherapeutic agents a reduction in the size of the primary 
tumor,  occasional sterilization of the bone marrow, and, rarely, transformation of the 
neuroblastoma into a benign ganglioneuroma  have been observed [24]. 
The current tendencies for the use of chemotherapy in the treatment of neuroblastoma 
include: dose-intensive chemotherapy followed by surgical excision of residual disease 
myeloablative therapy by combination of chemotherapeutic agents , followed by 
Autologous Bone Marrow Transplantationand biological responder modifiers, to bring 
about  differentiation of the tumor and to reduce the degree of bone marrow infiltration [40]. 
The multimodal therapeutic protocols outlined by POG are the norm of care for children 
diagnosed with neuroblastoma. 
Topotecan, an inhibitor of the topoisomerasa I, alone or in combination with  
Cyclophosphamide, has shown to have activity against recurrent neuroblastoma. This 
information has recently prompted the Children’s Oncology Group to design a study to 
prove the clinical effectiveness of incorporating Topotecan in an intensive induction 
régimen for  patients with high-risk neuroblastoma. 
Retinoic acid (RA), a biologically active form of vitamin A, plays a central role as a signaling 
molecule in the early stages of embryonic development and the generation of multiple organs 
and systems, including the Nervous System [59]. In vitro culture it has been demonstrated a 
decrease in the regulation of the expression of the N-myc messenger RNA which obstructs the 
proliferation of tumor cells. These observations taken to clinical trials demonstrated the 
efficacy of 13-cis RA in children with neuroblastoma in relapse. The results of phase I and II 
trials didn't show benefits in patients with high tumor load; however in patient with  minimal 
disease, phase III randomized trials involving , 13-cis RA produced an improved rate of 
survival from 20% - 40% in patient with high risk neuroblastoma [24]. 
Indirect immunotherapy has been evaluated as part of multimodal treatment of microscopic 
resistant neuroblastoma. Diasilganglioside (GD2) is an excellent target for immunotherapy 
because this antigen is overexpressed in the majority of human neuroblastoma. The 
response rate is reinforced for those that have used cytosine combinations along with anti-
GD2 antibodies, increasing the antibody dependent cellular cytotoxicity (ADCC). Other 
immunotherapies like cytotoxic T lymphocytes, modified dendritic cells, fusion protein Hu 
14.18-IL2 (immnunocytokine), GM-CSF, and interleukine-2 (IL-2) have shown promising 
results against neuroblastoma.  
The clinical trials in Europe and North America are delineating the effectiveness of the 
radio-tagged methyliodobenzylguanidine (MIBG) with I-131 with or without combination 
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myelobastic chemotherapy, followed by rescue with autologous stem cells. The optimal 
doses, schedules, and best timing for MIBG therapy are the goals of these clinical trials [25]. 
On the other hand, the therapy with antiangiogenesis has more than a theoretical role in the 
treatment of neuroblastoma. In fact, the preclinical studies have demonstrated that these 
agents inhibit the growth of neuroblastoma in vivo, mainly in minimal residual disease. 
Phase I protocols that test inhibitors of angiogenesis allow the determination if a very 
vascular neuroblastoma responds to these agents. 
In vitro cultures have demonstrated that neuroblastoma is radiosensitive, but the clinical 
trials carried out have been unclear and inconclusive. As a primary modality of treatment, 
radiation therapy still has a limited role. In metastatic regional lymph nodes sequential 
chemotherapy with cyclophosphamide can be used.  
Intensive multimodal treatment of patient with neuroblastoma has shown an increase in 
survival rate. However, the risk of therapy related delayed manifestations must be taken 
into consideration because of adverse, devastating effects. Survivors should be closely 
followed and supervised by multidisciplinary Centers to detect and document any long 
term sequelae. The Oncological Pediatric (GOP) Group recently developed a classification 
system named Neuroblastoma Risk Stratification System (NRSS). This new classification 
includes biological and clinical characteristics to predict behavior, similar to the Shimada 
Index and it is also used with the purpose of stratifying the treatment. The patients are 
classified in the categories of low, intermediate or high-risk according with the age at the 
diagnosis, the staging according to INSS, the histopathological features, the state of 
amplified N-myc and the DNA index. 
9. Protocols of treatments 
Low Risk Disease (Protocol I) 
Cyclophosphamide 400 mg /m2 /BS/ IV Day 1 
Vincristine 1.5 mg/ m2 /BS  /IV Day 1 
Adriamycin 30 mg/m2 /BS/ IV Day 8 
4 weeks rest. 
Total number of cycles: 6 
Intermediate risk (Protocol II) 
Block A* Dose Day 
Cyclophosphamide 1500 mg /m2 /BS/ IV Day 1 
Vincristine 1 mg /m2 /BS/ IV Day 1 and 2 
Rest 3  weeks 
Block B 
Cisplatin 120 mg /m2 /BS/ IV Day 1 
Etoposide 100 mg /m2 /BS /IV Day 1,2 and 3 
Rest 3 weeks 
Total of cycle: 6  
*In  stage III, the use of radiotherapy is recommended to help in the reduction of the primary tumor 
volume  during the weeks of  the first cycle of Block A plus 2 more weeks. 
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Considerations for surgery are taken as soon as the cytoreduction of the tumor is achieved. 
It is recommended to start evaluation for surgery from the third cycle. 
High risk disease (Protocol III) 
 
Block A* Dose Day 
Cyclophosphamide 1500 mg /m2 /BS/ IV Day 1 
Vincristine 1 mg /m2 /BS/ IV Day 1 and 2 
Rest  3  weeks 
Bloque B 
Cisplatin 120 mg /m2 /BS/ IV Day 1 
Etoposide 100 mg /m2 /BS /IV Day 1,2 and 3 
Block C Dose Day  
Adriamycin 60 mg /m2 /BS/ IV Day 1 and 2 
Rest 4 weeks 
Total cycles: 6 
Protocol according to clinical stages (Protocol IV, V, VI, VII ) 
 
STAGE Surgery Chemotherapy DAY Radiotherapy 
(Total Dose) 
I Complete 
resection of 
tumor 
   
II Complete 
resection of 
tumor 
VCR: 1.5 mg/ m2 /BS /IV* 
CFM:400 mg/ m2 /BS /IV* 
1,8,29 
1,3,7 
20 Gy* 
III 1 Partial 
resection or 
biopsy ** 
2 Rescue 
surgery*** 
VCR:1.5 mg/m2 /BS/ IV** 
CFM:300mg/ m2 /BS IV** 
ACTD:600mcg/m2/BS/ IV*** 
ADM: 100mg/m2 /BS IV** 
1,8,29 
1,3,7 
1,2,3,4 
 28 
 
VCR:1.5mg/ m2 /BS /EV** 
CFM:300mg/ m2 / BS EV** 
DTIC:300mg/m2  / BS EV** 
ADM: 40mg/ m2 / BS /EV** 
CDDP:100mg/m2/ BS EV** 
1,8,29 
2,3,4 
1,2,3,4 
8,29 
28 
20 Gy* 
 
 
 
 
IV 
 
 
 
 
VCR:1.5 mg/m2 / BS /EV** 
CFM:300mg/ m2/ BS /EV** 
ACTD:600mcg/m2/ BS EV** 
ADM:100mg/ m2 / BS EV** 
1,8,29 
1,3,7 
1,2,3,4 
28 
20 Gy* 
 
         
Alternative 
VCR: 1.5 mg/m/BS/IV** 
CFM:300mg/m2/BS /IV** 
DTIC:300/mg/m2/BS / IV** 
ADM: 40 mg/ m2/BS/ IV** 
CDDP:100mg/m2/BS/IV** 
 20 Gy 
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STAGE Surgery Chemotherapy DAY Radiotherapy 
(Total Dose) 
IVS Total resection 
or CAFF 
CFM*** 
ADM*** 
1,2,3,4,5,6,7
8 
 
Abbreviations:  
VCR: Vincristine 
CFM: Cyclophosphamide 
ACTD; Actinomycin D 
ADM: Doxorubicin 
DTIC: Dacarbazine 
CDDP: Cisplatin 
Surgery: 
*In the event of existing doubts that it is a true stage I, treatment should be done  with chemotherapy 
using the proposed outline for stage II cases. 
**It is preferably recommended to carry out fine needle aspiration biopsy (FNAB) of the primary tumor 
*** Surgery for biopsy specimen if there is cytoreduction of the initial tumor 
Chemotherapy: 
*Weekly treatment for 8 cycles, then biweekly for 8 cycles and then repeats the protocol until 
completing one year of treatment. 
**Rest for 3 weeks and then repeat a cycle every 3 weeks, to complete 4 cycles. 
 *** give a cycle every 3 weeks for 1 year. 
*VCR: 1.5 mg m2 BS IV 
*CFM: 300 mg m2 BS IV 
NOTE: When concluding the radiotherapy treatment , rest for 3 weeks and then  continue with the 
initial chemotherapy protocol, 1 cycle every 4 weeks until giving 4 cycles, and later on 1 cycle every 6 
weeks until giving 4 cycles, followed by 1 cycle every 8 weeks until completing 2 cycles. 
10. Radiotherapy 
For patient with low risk or neuroblastoma intermission in the plan of current treatment of 
COG (COG-ANBL0531), radiation therapy is reserved for patients with a symptomatic life-
threatening tumor which does not respond to chemotherapy. The treatment of children with 
low-risk stage 4S disease depends on clinical presentation - those who are clinically stable may 
not require therapy. However, the disease complications, such as respiratory distress from 
massive hepatomegaly may need a low intensity chemotherapy regimen (low dose 
cyclophosphamide). Resection of the primary tumor is not associated with improved outcome. 
In patients classified as intermediate risk with unfavorable biologic features, radiation 
therapy is given if residual viable tumor remains after 24 weeks of chemotherapy and 
secondlook surgery. 
For patients classified as high risk, the use of radiation therapy for local control after 
surgical resection is recommended whether or not complete tumor removal was obtained 
Schema of Hayes (Protocol VIII) 
Cyclophosphamide 150 mg /m2 /BS /IV Day 1 to 7 
Adriamycin 35 mg /m2 /BS /IV Day 8 
Rest for {of} 3 weeks 
Total of cycles: 6 
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Protocol OPEJ / OJEC (Protocol IX) 
OPEC 
Vincristine 1.5  mg m2 /BS /IV Day 1 
Cisplatin 80   mg m2  / BS/IV Day 1 
Etoposide 200 mg m2 / BS /IV  Day 3 
Cyclophosphamide 500 mg m2 / BS /IV  Day 1 
OJEC 
Vincristine 1.5  mg m2 /BS /IV Day 1 
Carboplatin 500 mg m2 /BS /IV Day 1 
Etoposide 200 mg m2 /BS /IV Day 1 
Cyclophosphamide 500 mg m2 /BS /IV Day 1 
Rest for 3 weeks 
Total of cycles: 7 
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